NCT05626803: A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers |
|
|
| Active, not recruiting | 2 | 135 | US | Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo | Vaxart | Norovirus Infections | 10/23 | 07/24 | | |
NCT06714955: Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects |
|
|
| Active, not recruiting | 1 | 30 | US | Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week. | BrightGene Bio-Medical Technology Co., Ltd. | Non-diabetic Overweight or Obese | 01/25 | 03/25 | | |
